Hyperacute serum therapy: pilot first-in-man results in knee osteoarthritis
Read moreHyperacute Serum promotes stem cell and cartilage cell regeneration
Two peer-reviewed studies showed that hypACT outperforms PRP as a regenerative serum. Krems an der Donau, Austria, 15 January 2018 – Hyperacute serum, a variety of platelet rich plasma (PRP), that has been developed for clinical use by OrthoSera...
Read moreNew Managing Director joins OrthoSera
Krems an der Donau, Austria, 1 September 2017 – OrthoSera GmbH, an orthobiologics company developing serum-based therapeutic solutions in orthopedics and the dental sector is pleased to announce the appointment of Dr. Tamás Miklós Polónyi, to the...
Read moreOrthoSera closes Series B financing round
hypACT™ serum therapy for the regeneration of osteoarthritic bone and cartilage is entering clinical development Krems an der Donau, Austria, 09 February 2017 – OrthoSera GmbH, an orthobiologics company developing serum-based solutions for...
Read moreOrthoSera Receives CE Mark for hypACT™ Device to Regenerate Osteoarthritic Bone
Krems an der Donau, Austria, September 07, 2016 / B3C newswire / — OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces that its proprietary serum technology is ready for...
Read moreBoneAlbumin induces better bone formation
Krems an der Donau, Austria, 29 June 2016 – OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces that a double-blind, controlled study with BoneAlbuminTM, the company’s first...
Read moreOrthoSera successfully closes financing round
Krems an der Donau, Austria, 4 December 2015 – Shortly after market launch of our first product BoneAlbumin via our separately funded dental subsidiary OrthoSera has managed to successfully close the first institutional investment round led by...
Read moreLacerta Technologies is now OrthoSera
Krems an der Donau, Austria, 26 November 2015 – Lacerta Technologies, an orthobiologics company developing serum-based solutions for musculoskeletal indications has reached a major milestone by putting their first product on the market...
Read moreLacerta announces positive results of double-blind controlled study on BoneAlbumin
At the International Conference ‘Unified Scientific Approaches towards Regenerative Orthopaedics and Dentistry’ in Venice, Italy, Dr. Lacza has announced the preliminary results of the first double-blind, controlled human study on...
Read moreLacerta signs manufacturing agreement for BoneAlbumin
Following the positive decision of Hungarian Authorities about the classification of BoneAlbumin as a tissue product, Lacerta signed a manufacturing agreement with West Hungarian Tissue Bank for the manufacturing of BoneAlbumin.
Read moreResearch Article was published on Increased Release Time of Antibiotics from Bone Allografts through a Novel Biodegradable Coating
Krems an der Donau, Austria, 22nd July 2014 – Lacerta Technologies has published a research article in cooperation with Semmelweis University and Singapore Bioimaging Consortium in the Journal “Biomed Research International”. Local...
Read moreNew Chief Business Officer at Lacerta Technologies GmbH
Krems an der Donau, Austria, 30th January 2014 – Lacerta Technologies has hired a new Chief Business Officer to strengthen the senior management team and to support the ramping up of the company’s clinical development and commercialization...
Read more